The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non‐carriers with mild cognitive impairment due to Alzheimer's disease

Documenti analoghi

• The HOPE4MCI study: AGB101 treatment reduces entorhinal cortex atrophy in patients with amnestic mild cognitive impairment due to Alzheimer's Disease who are ApoE‐4 non‐carriers
  di: Nisha Rani, et al.
  Pubblicazione: (2024)
• The HOPE4MCI study: A randomized double‐blind assessment of AGB101 for the treatment of MCI due to AD
  di: Richard Mohs, et al.
  Pubblicazione: (2024)
• The HOPE4MCI study: AGB101 treatment normalizes aberrant network activity and slows entorhinal cortex atrophy in patients with amnestic mild cognitive impairment due to Alzheimer's Disease who are ApoE‐4 non‐carriers
  di: Arnold Bakker, et al.
  Pubblicazione: (2025)
• Plasma amyloid beta biomarkers predict amyloid positivity and longitudinal clinical progression in mild cognitive impairment
  di: Takuya Ataka, et al.
  Pubblicazione: (2024)
• Mapping sex differences in brain and cognition in relation to APOE ε4 and amyloid burden: A longitudinal normative modelling study
  di: Sivaniya Subramaniapillai, et al.
  Pubblicazione: (2026)